Introduction: The SARS-CoV-2 pandemic has not only affected the health status of the world‘s population, but has also affected public and economic life in an unprecedented way, challenging health professionals. In 2019, ophthalmologist Dr. Wenliang from Wuhan was the first to report the emergence of a new virus similar to SARS. While diagnostic and therapeutic efforts are focused on controlling the respiratory and systemic complications of the infection, in the clinical practice of ophthalmologists a spectrum of ocular symptoms characteristic of the disease is recently formed. Our aim is to present our and the world experience in terms of ocular manifestations and their attitude to the course and prognosis of the systemic disease. Materials and methods: A detailed analysis of the patients with COVID-19 passed through the University First Hospital „Sveti Yoan Krastitel“ was made and was compared with data from world literature. Conclusion: COVID-19 can penetrate the ocular surface as a front door. The disease affects the eyes in many different aspects - from manifestations of the anterior segment of the eye, to the fundus.
World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/dg/ speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on- COVID-19. 11-march-2020. Accessed April 2020.
Centers for Disease Control and Prevention. People who are at higher risk for severe illness. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed March 2020.
American Academy of Ophthalmology. Important coronavirus updates for ophthalmologists. Available at: https://www.aao.org/headline/alert-important-coronavirus-context. Accessed March 2020.
Société Française d’Ophtalmologie. Quelle conduite à tenir adopter vis à vis des injections intravitréennes (IVT) dans cette période d’épidémie au Covid-19 – SARS-CoV-2? Available at: https://
www.sfo.asso.fr/files/files/FPHUNG/epidemie_au_ covid-19_-_ivt.pdf. Accessed March 2020.
Deutsche Ophthalmologische Gesellschaft. Coronavirus COVID-19. Available at: https://www.dog.org/?cat=288. Accessed March 2020.
The Royal College of Ophthalmologists. Medical retinal management plans during COVID-19. Available at: https://www.rcophth.ac.uk/wp-content/uploads/2020/03/ Medical-Retinal-Management-Plan-during-COVID-19-UPDATED-300320-1-2.pdf.Accessed April 2020.
The Royal College of Ophthalmologists. COVID-19 clinical guidance for ophthalmologists. Available at: https://www.rcophth.ac.uk/2020/03/covid-19-update-and-resources- for-ophthalmologists/. Accessed March 2020.
Japanese Ophthalmological Society. Guidance for ophthalmology-related healthcare workers regarding COVID-19. Available at: http://www.nichigan.or.jp/news/065.pdf. Accessed March 2020.
American Society of Retina Specialists. COVID-19: updates and resources. Available at: https://www.asrs.org/practice/asrs-member-alert-regarding-covid-19-pandemic. Accessed March 2020.
The Royal Australian and New Zealand College of Ophthalmologists. Corona virus (COVID-19) guideline. Available at: https://ranzco.edu/wp-content/uploads/2020/03/ RANZCO-Coronavirus-COVID-19-Guideline_01042020.pdf. Accessed March 2020.
The Royal Australian and New Zealand College of Ophthalmologists. RANZCO triage guidelines for fellows and other health professionals. Available at: https://ranzco.edu/ wp-content/uploads/2020/04/RANZCO-COVID-19-Triage-Guidelines-2020_4_1.pdf. Accessed March 2020.
Canadian Ophthalmological Society. Canadian Retina Society (CRS) position statement on intravitreal injections and the management of retinal diseases during the COVID-19 crisis. Available at: https://www.crssrc.ca/files/CRS-Position-Statement-on-Intravitreal-Injection-Treatments-Mar-19-2020.pdf. Accessed April 2020.
Yen MY, Schwartz J, Chen SY et al. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts. J Microbiol Immunol Infect, 2020.
Feng S, Shen C, Xia N et al. Rational use of face masks in the COVID-19 pandemic. Lancet Respir Med, 2020.
World Health Organization. Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts. Available at: https://www.who.int/publications-detail/
home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts. Accessed March 2020.
Bressler NM, Beaulieu WT, Glassman AR et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema withvision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol, 2018; 136 (3): 257-269.
Schmidt-Erfurth U, Lang GE, Holz FG et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology, 2014; 121 (5): 1045-1053.
Korobelnik JF, Loewenstein A, on behalf of the Vision Academy. Communicating with patients with nAMD and their families during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020.
World Health Organization. Coronavirus disease (COVID-19) advice for the public. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/ advice-for-public. Accessed March 2020.
Public Health England. Guidance on social distancing for everyone in the UK. Available at: https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults. Accessed March 2020.
World Health Organization. Advice on the use of masks in the context of COVID-19. Available at: https://apps.who.int/iris/bitstream/handle/10665/331693/WHO-2019- nCov-IPC_Masks-2020.3-eng.pdf?sequence=1&isAllowed=y. Accessed April 2020.
Wong TY, Lanzetta P, Bandello F et al. Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration: an expert panel consensus. Retina, 2020; 40 (4):599-611.
Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419-1431.
Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006; 355 (14): 1432-1444.
Email this article (Login required) 
